Skip to content

CG Oncology CGON Accounts Payable

Accounts Payable at other companies

Pfizer logo
PfizerPFE
$4.51B-14.0%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$10.46B+9.6%
Gilead Sciences logo
Gilead SciencesGILD
$645M-12.5%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$13.74M-2.9%
Celcuity logo
CelcuityCELC
$10.45M+5.3%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$7.54M-57.3%

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's accounts payable?
CG Oncology (CGON) reported accounts payable of $8.24M in Q1 2026.
How has CG Oncology's accounts payable changed year-over-year?
CG Oncology's accounts payable increased by 22.4% year-over-year, from $6.73M to $8.24M.
What is the long-term trend for CG Oncology's accounts payable?
Over 2 years (2023 to 2025), CG Oncology's accounts payable has grown at a 172.6% compound annual growth rate (CAGR), from $3.87M to $28.76M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.